Business Update
Isotechnika grants Lux Biosciences worldwide ophthalmic rights to ISA247
Published in Health and Medicine Week, June 22nd, 2006
ISA247 is a calcineurin inhibitor currently being investigated in a phase III trial for the treatment of moderate-to-severe psoriasis and a phase IIb trial for the prevention of organ rejection following transplantation.
Under the terms of the agreement:
1) Lux Biosciences, Inc., will make upfront and milestone payments to Isotechnika. Assuming...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
More Articles from Health and Medicine Week
- Behavioral Medicine
Proximity and visibility of a food can increase an adult's consumption of it - Gene Research
Dartmouth study finds that arsenic found in drinking water inhibits DNA repair - Obesity Epidemiology
Overweight and obesity associated with driving to work - SARS Infection Control
Perception of SARS as public health threat increases infection control compliance - Sexual & Reproductive Health
Differences in sexual desire can be attributed to genetic variances - Abdominal Aortic Aneurysms
Endologix receives U.S. Food and Drug Administration approval for Visiflex Delivery System - More from this issue of Health and Medicine Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
